Anzeige
Mehr »
Donnerstag, 09.10.2025 - Börsentäglich über 12.000 News
Kursrakete 2025: CiTech präsentiert sich u.a. mit DroneShield neben Palantir & Rheinmetall - welche News sind zu erwarten?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4ZZ0Z | ISIN: US7469641051 | Ticker-Symbol: DB0
Tradegate
08.10.25 | 20:41
2,540 Euro
-1,55 % -0,040
1-Jahres-Chart
Q32 BIO INC Chart 1 Jahr
5-Tage-Chart
Q32 BIO INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,6402,74011:44
2,6402,74011:08

Aktuelle News zur Q32 BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
Leser Medien
06.08.Q32 Bio August 2025 slides: Bempikibart shows durable response in alopecia areata10
06.08.Q32 Bio GAAP EPS of -$0.782
06.08.Q32 Bio Inc. - 10-Q, Quarterly Report-
06.08.Q32 Bio Inc. - 8-K, Current Report-
06.08.Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update173-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 -- -- Strengthened...
► Artikel lesen
11.07.Pre-market Movers: Above Food Ingredients, Future FinTech Group, LM Funding America, Capricor Therapeutics, Q32 Bio1.086OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.15 A.M. ET).In the Green Above Food Ingredients Inc. (ABVE) is up over 115%...
► Artikel lesen
25.06.Q32 Bio Inc. - 8-K, Current Report1
Q32 BIO Aktie jetzt für 0€ handeln
25.06.Q32 Bio names interim chief medical officer1
17.06.Q32 Bio Inc. - 8-K, Current Report1
23.05.Q32 Bio erhält Mitteilung über Nichteinhaltung der Nasdaq-Vorschriften9
23.05.Q32 Bio Inc. - 8-K, Current Report2
08.05.Q32 Bio GAAP EPS of -$0.903
08.05.Q32 Bio Inc. - 10-Q, Quarterly Report2
08.05.Q32 Bio Inc. - 8-K, Current Report1
08.05.Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update230-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open-label extension (OLE)...
► Artikel lesen
30.04.Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata204WALTHAM, Mass., April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative...
► Artikel lesen
25.04.Q32 Bio Inc. - 8-K, Current Report5
16.04.Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata197-- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company")...
► Artikel lesen
11.03.Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update196-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated...
► Artikel lesen
08.03.Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting149-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1